We are live on ! Find out more
RVNC

Revance Therapeutics, Inc.
RVNC

Delisted

RVNC was delisted on the 5th of February, 2025.

Back to rankings

120 hedge funds and large institutions have $1.05B invested in Revance Therapeutics, Inc. in 2018 Q1 according to their latest regulatory filings, with 21 funds opening new positions, 52 increasing their positions, 26 reducing their positions, and 16 closing their positions.

New
Increased
Maintained
Reduced
Closed

132% more call options, than puts

Call options by funds: $3.14M | Put options by funds: $1.35M

100% more repeat investments, than reductions

Existing positions increased: 52 | Existing positions reduced: 26

31% more first-time investments, than exits

New positions opened: 21 | Existing positions closed: 16

4% more funds holding

Funds holding: 115 → 120 (+5)

16% less capital invested

Capital invested by funds: $1.25B → $1.05B (-$196M)

33% less funds holding in top 10

Funds holding in top 10: 3 → 2 (-1)

Holders
120
Holders Change
+5
Holders Change %
+4.35%
% of All Funds
2.75%
Holding in Top 10
2
Holding in Top 10 Change
-1
Holding in Top 10 Change %
-33.33%
% of All Funds
0.05%
New
21
Increased
52
Reduced
26
Closed
16
Calls
$3.14M
Puts
$1.35M
Net Calls
+$1.79M
Net Calls Change
+$8.8M

Top Buyers

Rank Fund Capital Flow
1
Jennison Associates
Jennison Associates
New York
+$20.1M
2
Millennium Management
Millennium Management
New York
+$12.7M
3
FI
Fosun International
China
+$10.3M
4
BlackRock
BlackRock
New York
+$7.79M
5
Wellington Management Group
Wellington Management Group
Massachusetts
+$7.75M

Top Sellers

Rank Fund Capital Flow
1
NCM
NovaQuest Capital Management
North Carolina
-$49.5M
2
DM
Deerfield Management
New York
-$35.8M
3
GPP
Great Point Partners
Connecticut
-$10.7M
4
SAM
Senzar Asset Management
New York
-$8.45M
5
Franklin Resources
Franklin Resources
California
-$7.11M
Name Holding Trade Value Shares
Change 		Change in
Stake
Charles Schwab
26
Charles Schwab
California
$4.15M +$525K +16,307 +14%
Principal Financial Group
27
Principal Financial Group
Iowa
$3.88M -$5.15K -160 -0.1%
EI
28
EAM Investors
California
$3.48M +$185K +5,763 +5%
EIM
29
Essex Investment Management
Massachusetts
$3.43M -$244K -7,592 -6%
Citadel Advisors
30
Citadel Advisors
Florida
$2.61M +$1.58M +49,157 +139%
SSA
31
Schonfeld Strategic Advisors
New York
$2.58M -$375K -11,657 -12%
Invesco
32
Invesco
Georgia
$2.56M +$2.67M +83,097 New
USAA
33
United Services Automobile Association
Texas
$2.46M +$45K +1,399 +2%
Allianz Asset Management
34
Allianz Asset Management
Germany
$2.45M +$363K +11,271 +17%
PPA
35
Parametric Portfolio Associates
Washington
$2.24M -$193 -6 -0%
TCIM
36
TIAA CREF Investment Management
New York
$2.07M +$141K +4,372 +7%
ARTA
37
A.R.T. Advisors
New York
$2.02M +$113K +3,500 +6%
WRF
38
Waddell & Reed Financial
Kansas
$1.97M – – –
QI
39
QS Investors
New York
$1.95M -$171K -5,303 -8%
Victory Capital Management
40
Victory Capital Management
Texas
$1.93M +$221K +6,860 +12%
Goldman Sachs
41
Goldman Sachs
New York
$1.82M +$1.04M +32,475 +122%
Federated Hermes
42
Federated Hermes
Pennsylvania
$1.8M +$651K +20,245 +53%
Ameriprise
43
Ameriprise
Minnesota
$1.72M -$286K -8,897 -14%
TA
44
Teachers Advisors
New York
$1.58M +$284K +8,837 +21%
Swiss National Bank
45
Swiss National Bank
Switzerland
$1.57M -$19.3K -600 -1%
PAM
46
Panagora Asset Management
Massachusetts
$1.54M +$1.61M +49,934 New
MWNA
47
Marshall Wace North America
New York
$1.53M +$849K +26,385 +113%
AA
48
ALPS Advisors
Colorado
$1.48M +$441K +13,702 +40%
Two Sigma Investments
49
Two Sigma Investments
New York
$1.47M -$1.17M -36,287 -43%
EGI
50
EAM Global Investors
California
$1.38M – – –
1
2
3 4 5

RVNC Hedge Fund Activity: Q1 2018 in Review

120 of the 4,364 institutional investors tracked by Wall St. Rank reported a position in Revance Therapeutics, Inc. (RVNC) for Q1 2018, worth a combined $1.05B — down 16% from $1.25B a quarter earlier.

Buyers outnumbered sellers: 21 funds opened new RVNC positions and 16 closed out — a net gain of 5 holders — while 52 added to existing stakes and 26 trimmed.

The largest buyer was Jennison Associates, adding an estimated $20.1M. The largest seller was NovaQuest Capital Management, cutting an estimated $49.5M.

  • 120 institutional investors held Revance Therapeutics, Inc. (RVNC) as of Q1 2018, up from 115 in Q4 2017.
  • Funds reported $1.05B of Revance Therapeutics, Inc. stock for Q1 2018, down 16% quarter-over-quarter.
  • 21 funds opened new Revance Therapeutics, Inc. positions in Q1 2018 and 16 closed out, a net change of +5 holders.
  • The largest Revance Therapeutics, Inc. buyer in Q1 2018 was Jennison Associates, an estimated $20.1M added.
  • The largest Revance Therapeutics, Inc. seller in Q1 2018 was NovaQuest Capital Management, an estimated $49.5M sold.

Based on aggregated 13F filings for Q1 2018.